-$0.85 Earnings Per Share Expected for argenx SE – (ARGX) This Quarter

Analysts expect argenx SE – (NASDAQ:ARGX) to post earnings of ($0.85) per share for the current quarter, Zacks reports. Three analysts have issued estimates for argenx’s earnings, with the highest EPS estimate coming in at ($0.66) and the lowest estimate coming in at ($1.01). The company is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that argenx will report full year earnings of ($3.68) per share for the current fiscal year, with EPS estimates ranging from ($4.45) to ($3.25). For the next year, analysts forecast that the business will post earnings of ($5.02) per share, with EPS estimates ranging from ($6.03) to ($3.85). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for argenx.

Several brokerages have recently weighed in on ARGX. Wedbush upped their target price on shares of argenx from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Tuesday, December 4th. Zacks Investment Research cut shares of argenx from a “buy” rating to a “hold” rating in a report on Monday, December 24th. Stifel Nicolaus reaffirmed a “buy” rating on shares of argenx in a report on Monday, February 4th. Wolfe Research initiated coverage on shares of argenx in a research report on Friday, December 14th. They issued an “outperform” rating for the company. Finally, ValuEngine upgraded shares of argenx from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. One analyst has rated the stock with a sell rating and thirteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $140.91.

Institutional investors and hedge funds have recently made changes to their positions in the stock. DekaBank Deutsche Girozentrale bought a new position in argenx in the 3rd quarter valued at about $3,746,000. BB Biotech AG boosted its position in shares of argenx by 20.4% during the 4th quarter. BB Biotech AG now owns 884,739 shares of the company’s stock valued at $84,997,000 after purchasing an additional 150,000 shares in the last quarter. Perceptive Advisors LLC boosted its position in shares of argenx by 5.9% during the 3rd quarter. Perceptive Advisors LLC now owns 560,941 shares of the company’s stock valued at $42,541,000 after purchasing an additional 31,381 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of argenx by 1,715.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,429 shares of the company’s stock valued at $1,170,000 after purchasing an additional 14,579 shares in the last quarter. Finally, Laurion Capital Management LP bought a new position in shares of argenx during the 3rd quarter valued at about $10,693,000. Hedge funds and other institutional investors own 63.72% of the company’s stock.

ARGX traded down $1.42 during trading on Friday, hitting $127.49. 3,606 shares of the company’s stock were exchanged, compared to its average volume of 151,156. argenx has a 1 year low of $63.81 and a 1 year high of $135.58. The company has a market cap of $4.09 billion, a P/E ratio of -54.33 and a beta of 1.23.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: Return on Investment (ROI)

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.